Zobrazeno 1 - 10
of 27
pro vyhledávání: '"E. M. G. J. de Jong"'
Autor:
C. A. M. van Riel, C. A. J. Michielsens, M. E. van Muijen, L. S. van der Schoot, J. M. P. A. van den Reek, E. M. G. J. de Jong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/a0f47887ce2a481489582565d8534a82
Autor:
C. D. Wortman, L. T. H. Godding, Q. Yin, K. V. Kwee, M. B. Visch, E. M. G. J. de Jong, J. M. P. A. van den Reek, M. Tjioe
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background During the COVID-19 pandemic, psoriasis care underwent significant changes in consultation methods and treatment management. However, comprehensive data on these changes and patient perceptions are limited.Aims To evaluate the pandemic’s
Externí odkaz:
https://doaj.org/article/455c52ee7de348c1899d8a83dfa80028
Autor:
C. A. M. van Riel, C. A. J. Michielsens, M. E. van Muijen, L. S. van der Schoot, J. M. P. A. van den Reek, E. M. G. J. de Jong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The literature on the DR of the newest generation of biologics (IL-17/23i)
Externí odkaz:
https://doaj.org/article/d96b176483684acb84df09af3da5c14a
Autor:
L. S. van der Schoot, L. M. Verhoef, I. van Ee, F. P. A. H. van Oort, A. H. Pieterse, M. M. B. Seyger, E. M. G. J. de Jong, J. M. P. A. van den Reek
Publikováno v:
Archives of Dermatological Research.
Dose reduction of biologics for psoriasis could contribute to more efficient use of these expensive medicines. Evidence on opinions of patients with psoriasis regarding dose reduction is sparse. The objective of this study was therefore to explore pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c9a6840a035869b87360535094637a1
https://doi.org/10.1007/s00403-023-02566-w
https://doi.org/10.1007/s00403-023-02566-w
Autor:
E. L. M. ter Haar, S. E. Thomas, J. M. P. A. van den Reek, M. E. Otero, M. D. Njoo, P. M. Ossenkoppele, E. N. Kop, S. R. P. Dodemont, J. E. M. Körver, A. L. A. Kuijpers, R. J. Lindhout, R. A. Tupker, J. M. Mommers, M. A. M. Berends, M. I. A. Koetsier, M. S. de Bruin-Weller, M. B. Visch, W. P. Arnold, P. P. M. van Lümig, M. M. Kleinpenning, S. F. K. Lubeek, E. M. G. J. de Jong
Publikováno v:
Drugs & Aging, 39(9), 715-727. Adis International Ltd
Drugs & Aging, 39, 715-727
Drugs & Aging, 39, 9, pp. 715-727
Drugs & Aging, 39, 715-727
Drugs & Aging, 39, 9, pp. 715-727
Contains fulltext : 282870.pdf (Publisher’s version ) (Open Access) BACKGROUND: Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cef7cbf16288c7e8041ef65fccf89e3
https://cris.maastrichtuniversity.nl/en/publications/fdce1bae-b731-41fc-9fbf-793605b45917
https://cris.maastrichtuniversity.nl/en/publications/fdce1bae-b731-41fc-9fbf-793605b45917
Publikováno v:
Annals of the Rheumatic Diseases. 81:857-858
BackgroundOne in three patients with psoriasis (Pso) will develop psoriatic arthritis (PsA). Active PsA can lead to disability and joint damage. Current screening methods are targeted at finding all PsA patients in a Pso population. However, PsA pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abcddf40ea54b2f7212f1e75319e485f
https://doi.org/10.1136/annrheumdis-2022-eular.970
https://doi.org/10.1136/annrheumdis-2022-eular.970
Autor:
M. L. M. Mulder, J. E. Vriezekolk, T. Van Hal, L. Nieboer, N. Den Broeder, E. M. G. J. De Jong, A. Den Broeder, F. Van den Hoogen, P. Helliwell, M. Wenink
Publikováno v:
Annals of the Rheumatic Diseases. 81:259.1-259
BackgroundConventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) are the cornerstone first-line treatment in psoriatic arthritis (PsA), although there is a paucity of evidence for the effectiveness of csDMARDs and especially their c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0940fe0c732ad4712c4b4427eca6b31a
https://doi.org/10.1136/annrheumdis-2022-eular.2042
https://doi.org/10.1136/annrheumdis-2022-eular.2042
Publikováno v:
Proceedings of the Society for Experimental Biology and Medicine. 222:1-8
The strong female predilection of systemic sclerosis, especially in women after their childbearing years, and the clinical and histopathological similarities with chronic graft-versus-host disease make systemic sclerosis an interesting subject of deb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac59cbb5060f1b8efc1d6a3dc2ed5e15
https://doi.org/10.1111/j.1525-1373.1999.09991.pp.x
https://doi.org/10.1111/j.1525-1373.1999.09991.pp.x
Publikováno v:
Journal of the European Academy of Dermatology and Venereology : JEADV. 27(8)
Most psoriasis patients suffering from mild to moderate disease are treated with first-line topical treatments, including corticosteroids, vitamin D analogues, topical retinoids and calcineurin inhibitors. Although evidence-based guidelines on combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::536a241dc7a1d74c81a7599012a419b0
https://pubmed.ncbi.nlm.nih.gov/23279069
https://pubmed.ncbi.nlm.nih.gov/23279069
Publikováno v:
Journal of the European Academy of Dermatology and Venereology : JEADV. 27(4)
Despite the availability of newer topical treatments, classical topical treatments for chronic plaque psoriasis still have an important position for selected patient populations. The vast majority of patients are treated with a combination of topical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b058f42167f8bb8115c72abf3726724d
https://pubmed.ncbi.nlm.nih.gov/22779910
https://pubmed.ncbi.nlm.nih.gov/22779910